Back to catalogue
RENX

Renalytix PLC

Health Care First-pass screen £7.87m
510/1000 Overall fit
AI beneficiary 35% 75
Operating leverage 25% 35
Valuation 25% 30
Downside protection 15% 57

First-pass take

Renalytix is an AI-native diagnostics developer with FDA Breakthrough designation for KidneyIntelX™, an ML algorithm identifying fast-progressing kidney disease. Strong partnerships and regulatory progress evidenced, but entirely pre-revenue with binary commercial/regulatory risks. Net cash of ~$26m provides runway.

Flags

pre-revenueloss-makingnet-cashclinical-stageno-valuation-data